PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland

Yoshimura, Tsuyoshi; Higashi, Shotaro; Yamada, Sohsuke; Noguchi, Hirotsugu; Nomoto, Mitsuharu; Suzuki, Hajime; Ishida, Takayuki; Takayama, Hirotaka; Hirano, Yuka; Yamashita, Masaru; Tanimoto, Akihide; Nakamura, Norifumi

doi:10.3390/cancers14010054

Cited by 7 publications

(9 citation statements)

References 31 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent molecular studies have described the overexpression of HER2 and EGFR in primary salivary gland MECs [23,24]. To our knowledge, these findings have not yet been described in thyroid MECs, but more research is needed, as such receptors may prove to be the gate towards targeted therapy, especially in advanced disease.…”

Section: Discussionmentioning

confidence: 94%

“…Other therapeutic choices include platinum-based chemotherapy and other alkylating agents, conventional radiotherapy, and radioiodine therapy, but they have shown little benefit. More recently, HER2 overexpression has been described in MECs of salivary gland origin, which could prove useful for targeted therapy, but no such reports exist on primary thyroid MECs as of yet [23,24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Aggressive Primary Thyroid Mucoepidermoid Carcinoma with Extensive Pulmonary Involvement

Mitrache,

Terzea,

Sirbu

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Mucoepidermoid carcinomas (MECs) represent the most common malignant neoplasms of the salivary glands, but they have also been described in other unusual sites. Primary MECs originating in the thyroid gland are exceedingly rare, accounting for less than 0.5% of thyroid tumors. Owing to their low to medium grade, they are usually associated with an indolent evolution and a good long-term prognosis, generally being managed surgically based on the extent of the disease. However, this does not always apply, as primary thyroid MECs may present as metastatic or locally advanced diseases. While several treatment options have been explored in such cases, no consensus currently exists on their optimal treatment plan, and they should be managed in a multidisciplinary fashion. We report the case of a 67-year-old patient with primary MEC of the thyroid, which behaved aggressively, with extensive pulmonary metastasis, ultimately leading to the rapid clinical deterioration and death of the patient.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Aggressive Primary Thyroid Mucoepidermoid Carcinoma with Extensive Pulmonary Involvement

Mitrache,

Terzea,

Sirbu

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…The unexpected discovery of new effective prognostic markers or therapeutic targets can help to reduce cancer mortality and improve survival rates. For example, in mucoepidermoid carcinoma, the discovery of PCP4/PEP19 and HER2 as novel prognostic markers is conducive to solving the problem of poor prognosis of cancer and can also be used in molecular-targeted therapies ( 31 ). At the same time, some molecular subtypes of tumors cannot be explained by standard clinical parameters or commonly used biomarkers; the emergence of the renin–angiotensin system genes as a new prognostic marker of acute myeloid leukemia (AML) may solve this problem ( 32 ).…”

Section: Discussionmentioning

confidence: 99%

Pan-Cancer Analysis Based on EPOR Expression With Potential Value in Prognosis and Tumor Immunity in 33 Tumors

2022

View full text Add to dashboard Cite

BackgroundErythropoietin receptor (EPOR), a member of the cytokine class I receptor family, mediates erythropoietin (EPO)-induced erythroblast proliferation and differentiation, but its significance goes beyond that. The expression and prognosis of EPOR in cancer remain unclear.MethodsThis study intended to perform a pan-cancer analysis of EPOR by bioinformatics methods. Several databases such as GTEx, TCGA, CCLE, and others were used to explore the overall situation of EPOR expression, and the correlation of EPOR expression with prognosis, microRNAs (miRNAs), immune infiltration, tumor microenvironment, immune checkpoint genes, chemokines, tumor mutation burden (TMB), microsatellite instability (MSI), methyltransferases, and DNA mismatch repair (MMR) genes in 33 tumors was analyzed. In addition, we compared the promoter methylation levels of EPOR in cancer tissues with those in normal tissues and performed protein–protein interaction network, gene–disease network, and genetic alteration analyses of EPOR, and finally enrichment analysis of EPOR-interacting proteins, co-expressed genes, and differentially expressed genes.ResultsThe TCGA database showed that EPOR expression was upregulated in BLCA, CHOL, HNSC, KIRC, LIHC, STAD, and THCA and downregulated in LUAD and LUSC. After combining the GTEx database, EPOR expression was found to be downregulated in 18 cancer tissues and upregulated in 6 cancer tissues. The CCLE database showed that EPOR expression was highest in LAML cell lines and lowest in HNSC cell lines. Survival analysis showed that high EPOR expression was positively correlated with OS in LUAD and PAAD and negatively correlated with OS in COAD, KIRC, and MESO. Moreover, EPOR had a good prognostic ability for COAD, LUAD, MESO, and PAAD and also influenced progression-free survival, disease-specific survival, disease-free survival, and progression-free interval in specific tumors. Further, EPOR was found to play a non-negligible role in tumor immunity, and a correlation of EPOR with miRNAs, TMB, MSI, and MMR genes and methyltransferases was confirmed to some extent. In addition, the enrichment analysis revealed that EPOR is involved in multiple cancer-related pathways.ConclusionThe general situation of EPOR expression in cancer provided a valuable clinical reference. EPOR may be target gene of hsa-miR-575, etc. A pan-cancer analysis of panoramic schema revealed that EPOR not only may play an important role in mediating EPO-induced erythroblast proliferation and differentiation but also has potential value in tumor immunity and is expected to be a prognostic marker for specific cancers.

show abstract

“…Commonly, neoplasm represents as a painless tumefaction engendering discomfort and localized pressure with variable adherence to circumscribing soft tissue. Neoplasm may appear as a rubbery or soft tumefaction [2,3] High grade mucoepidermoid carcinoma exhibits extensively cellular aspirates. Tumour cells depict high grade nuclear features constituted of pleomorphic nuclei incorporated with prominent nucleoli.…”

Section: Introductionmentioning

confidence: 99%

“…Upon frozen section, high grade mucoepidermoid carcinoma may be misinterpreted as squamous cell carcinoma [3,4].…”

Section: Introductionmentioning

confidence: 99%

Mire and Pelage-Mucoepidermoid Carcinoma Salivary Gland

2023

MJCCS

View full text Add to dashboard Cite

Mucoepidermoid carcinoma of salivary gland is a frequently encountered, malignant neoplasm arising from salivary gland epithelium constituted of mucous cells, intermediate cells and epidermoid cells. Tumefaction is associated with specific chromosomal translocation t(11;19)(q14-21;p12-13) and CRTC1(MECT1)-MAML2 genetic fusion. Median age of disease emergence is 49 years and a mild female preponderance is observed. Neoplasm predominantly incriminates major salivary glands as the parotid gland. Tumefaction depicts a solid, cystic or dual configuration and is composed of neoplastic epidermoid cells demonstrating solid nests, sheets or cellular cords along with varying proportion of epidermoid cells, intermediate cells or mucocytes. Tumour cells appear immune reactive to pan-cytokeratin, CK5/6, p63, p40, epithelial membrane antigen(EMA), CK7 or CK14. Membrane bound mucins appear immune reactive to MUC1, MUC2, MUC4, MUC5AC and MUC5B. Mucoepidermoid carcinoma requires segregation from neoplasms such as pleomorphic adenoma with squamous cell and mucinous cell metaplasia, necrotizing sialometaplasia, Warthin tumour with squamous metaplasia, acinic cell carcinoma, mammary analogue secretory carcinoma (MASC), primary or secondary squamous cell carcinoma or salivary duct carcinoma. Preoperative assessment with ultrasonography or fine needle aspiration cytology may be beneficially employed. Tumefaction may be subjected to comprehensive surgical eradication with excision of broad perimeter of uninvolved, circumscribing soft tissue.

show abstract

PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland

Cited by 7 publications

References 31 publications

Aggressive Primary Thyroid Mucoepidermoid Carcinoma with Extensive Pulmonary Involvement

Aggressive Primary Thyroid Mucoepidermoid Carcinoma with Extensive Pulmonary Involvement

Pan-Cancer Analysis Based on EPOR Expression With Potential Value in Prognosis and Tumor Immunity in 33 Tumors

Mire and Pelage-Mucoepidermoid Carcinoma Salivary Gland

Contact Info

Product

Resources

About